LeMaitre Vascular, Inc. (LMAT) – What Are Brokerages Saying About This Stock?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned an average rating of “Hold” from the nine ratings firms that are presently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $105.60.

Several analysts have issued reports on LMAT shares. Seaport Research Partners set a $110.00 price target on LeMaitre Vascular in a report on Thursday. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Wells Fargo & Company lowered their price objective on LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating on the stock in a research report on Thursday. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Finally, Citizens Jmp assumed coverage on LeMaitre Vascular in a research report on Thursday. They set a “market outperform” rating and a $110.00 target price for the company.

More LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Citizens JMP initiated coverage with a “Market Outperform” rating and a $110 price target, implying substantial upside from the share price cited in the report. Citizens JMP price target
• Positive Sentiment: Third-quarter revenue rose 11.3% year over year to $67.97 million, topping analysts’ expectations of $67.39 million. The company also declared a $0.25 dividend. Quarterly results Dividend announcement
• Neutral Sentiment: Management plans to participate in three upcoming investor conferences; the announcement did not provide new financial guidance. Investor conferences
• Negative Sentiment: Third-quarter EPS of $0.65 missed the $0.69 consensus and declined from $0.75 a year earlier. Reports also pointed to a cautious outlook, which may outweigh the revenue beat and help explain investor concern. Q3 earnings miss Q3 outlook analysis
• Negative Sentiment: Barrington lowered its price target to $91 from $95, though it maintained an Outperform rating. The reduced target signals less near-term upside in that firm’s view. Barrington price-target change

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT opened at $80.89 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 12.54 and a current ratio of 14.60. The firm has a market capitalization of $1.85 billion, a P/E ratio of 29.41, a P/E/G ratio of 2.38 and a beta of 0.51. The stock has a 50 day moving average price of $81.48 and a 200-day moving average price of $94.11. LeMaitre Vascular has a 52-week low of $78.22 and a 52-week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). The company had revenue of $67.97 million for the quarter, compared to the consensus estimate of $67.39 million. LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.33%. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter last year, the company earned $0.75 EPS. As a group, equities research analysts anticipate that LeMaitre Vascular will post 2.83 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 19th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 1.2%. The ex-dividend date is Thursday, November 19th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 36.36%.

Institutional Trading of LeMaitre Vascular

Large investors have recently made changes to their positions in the business. Catalyst Capital Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the first quarter valued at $32,000. Sterling Capital Management LLC boosted its stake in shares of LeMaitre Vascular by 844.2% during the 3rd quarter. Sterling Capital Management LLC now owns 727 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 650 shares during the period. Nykredit A S bought a new position in LeMaitre Vascular during the 2nd quarter valued at about $82,000. Northwestern Mutual Wealth Management Co. bought a new position in LeMaitre Vascular during the 2nd quarter valued at about $102,000. Finally, EverSource Wealth Advisors LLC grew its holdings in LeMaitre Vascular by 28.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier’s stock valued at $152,000 after purchasing an additional 308 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.